Sitryx
PrivateLast Round
Series A
Extension
Sep 27, 2023
Total Funding Raised
$89M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Sitryx is a biopharmaceutical company that develops disease-modifying therapeutics in immuno-oncology and immuno-inflammation by regulating cell metabolism.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sitryx Comparables
Compare Sitryx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| META Pharmaceuticals Inc. | 82% | |
| Lmito Therapeutics | 79% | |
| Aclaris Therapeutics | 76% |
Sitryx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Sep 27, 2023 | ||||
| Corporate Funding | Mar 31, 2020 | ||||
| Corporate Funding | Mar 1, 2020 | ||||
| Series A | Oct 8, 2018 |
Key People
Founding team and executive leadership
Sitryx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Seed, Series A Extension, Series A |
| Oxford Science Enterprises | Series A Extension |
| Oxford Science Enterprises | Series A Extension |
| Sofinnova Partners | Series A Extension, Series A |
| Longwood Fund | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 80% MoM, reaching 5.5K.
- Apr 2, 2026
Lead glutaminase-1 (GLS1) inhibitor nominated for development.
Sitryx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Sitryx's valuation, stock price, and market status.
Is Sitryx a public or private company?
Sitryx is a private company.
What is the current stock price of Sitryx?
Sitryx is a private company with no public stock price. No recent secondary market data is available.
How much is Sitryx worth (valuation)?
Valuation information for Sitryx is not publicly available.
Can I buy Sitryx stock?
Sitryx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Sitryx's last funding round?
Sitryx's most recent funding round was Series B on September 27, 2023.
Who are the main investors in Sitryx?
Key investors in Sitryx include SV Health Investors, Oxford Science Enterprises, Oxford Science Enterprises, Sofinnova Partners.
Will Sitryx IPO soon?
No public IPO plans have been announced for Sitryx.
How can I track Sitryx secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sitryx's secondary market activity and sign up for updates.